Study of Clinical Profile of COVID-19 Patients with Respect to COVID-19 Vaccination Status: An Analytical Study from a Tertiary Care Center in India

Document Type : Original Article

Authors

1 Department of General Medicine, L.N. Medical College and Research Centre, Bhopal, Madhya Pradesh, India

2 Department of Community Medicine, LN Medical College and Research Centre, Bhopal, Madhya Pradesh, India

Abstract

Background and aim: India is witnessing the third wave of COVID-19 in the background of the vaccination program in 2021. Many studies are being done worldwide to evaluate the short-term and long-term impact of vaccines. This study was done to determine the impact of vaccines on the clinical status of the patients that came to our tertiary care center.
Material and methods: An observational study was done at LN Medical College and JK Hospital Bhopal. Data were tabulated in MS Excel spreadsheets. Fisher Exact test was used as a statistical tool to calculate the p-value to assess the association's significance level.
Results: Out of 61 patients, male patients were more than female. The younger age group was more likely to require home isolation. Vaccinated patients were significantly found to have less probability of needing hospitalization (p=0.0192), less duration of stay in hospital (p=0.0081), and less chances of needing Intensive Care Units (ICU) support (p=0.0254). We also evaluated the impact of vaccines in patients with co-morbidities and without co-morbidities.
Conclusions: Vaccination against COVID-19 has proved to help mitigate the damage caused so far by COVID-19. However, the real-life effectiveness of vaccines in different individuals with different co-morbidities and other influencing factors should be studied in depth so vaccine programs can progress before the virus evolves.

Keywords

Main Subjects

References

[1]  Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The current second wave and COVID-19 vaccination status in India. Brain, behavior, and immunity. 2021;96:1-4. https://doi.org/10.1016/j.bbi.2021.05.018.
[2]  Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495. https://doi.org/10.1016/j.eclinm.2020.100495.
[3]  Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology. 2021;19(7):409-24. https://doi.org/10.1038/s41579-021-00573-0.
[4]  Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Influenza and Other Viruses in the Acutely Ill (IVY) Network. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States. Clin Infect Dis. 2021. https://doi.org/10.1001/jama.2021.19499.
[5]  Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. npj Vaccines. 2021;6(1):1-7. https://doi.org/10.1038/s41541-021-00327-2.
[6]  Chandani S, Jani D, Sahu PK, Kataria U, Suryawanshi S, Khubchandani J, et al. COVID-19 vaccination hesitancy in India: State of the nation and priorities for research. Brain, Behavior, & Immunity-Health. 2021;18:100375. https://doi.org/10.1016/j.bbih.2021.100375.
[7]  Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. New England Journal of Medicine. 2022;386(4):340-50. https://doi.org/10.1056/NEJMoa2115481.
[8]  Prunas O, Weinberger DM, Pitzer VE, Gazit S, Patalon T. Waning effectiveness of the BNT162b2 vaccine against infection in adolescents. medRxiv. 2022. https://doi.org/10.1101/2022.01.04.22268776.
[9]  Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nature medicine. 2022;28(4):831-7.  https://doi.org/10.1038/s41591-022-01699-1.
[10] Varghese GM, John R, Manesh A, Karthik R, Abraham OC. Clinical management of COVID-19. The Indian journal of medical research. 2020;151(5):401-10. https://doi.org/ 10.4103/ijmr.IJMR_957_20.
[11] Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. Jama. 2022;327(6):583-4. https://doi.org/10.1001/jama.2021.24868.
[12] Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on COVID-19 outbreaks in the United States. https://doi.org/10.1101/2020.11.27.20240051.
[13] Ojo TO, Adetunji TA, Amuda AA, Fajobi O, Elugbaju OT, Adeoye OE, et al. Clinical Profile and Outcome of COVID-19 Cases Admitted at a Tertiary Health Facility In South-West Nigeria. West African Journal of Medicine. 2022;39(3):241-7.
[14] Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. bmj. 2021;374. https://doi.org/10.1136/bmj.n2244.
[15] Muthukrishnan J, Vardhan V, Mangalesh S, Koley M, Shankar S, Yadav AK, et al. Vaccination status and COVID-19 related mortality: a hospital based cross sectional study. medical journal armed forces india. 2021;77:S278-82. https://doi.org/10.1016/j.mjafi.2021.06.034.
[16] Verma M, Sharma S, Kumar A, Hakim A, Bhansali S, Meena R. Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. Cureus. 2022;14(1): e21721.
How to Cite this Article: Verma I, Kumar A, Antony J, Ansari SA, Kaushal R, Rajput DP. Study of Clinical Profile of COVID-19 Patients with Respect to COVID-19 Vaccination Status: An Analytical Study from a Tertiary Care Center in India. International Journal of Scientific Research in Dental and Medical Sciences. 2022;4(2):57-66. http://doi.org/10.30485/IJSRDMS.2022.339254.1289.
 [17] Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. The Lancet. 2021;397(10292):2331-3. https://doi.org/10.1016/S0140-6736(21)01290-3.
[18] Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. 2022;22(1):43-55. https://doi.org/10.1016/S1473-3099(21)00460-6.
[19] Hoes J, Boef AG, Knol MJ, De Melker HE, Mollema L, Van der Klis FR, et al. Socioeconomic status is associated with antibody levels against vaccine preventable diseases in the Netherlands. Frontiers in public health. 2018;6:209. https://doi.org/10.3389/fpubh.2018.00209.
[20] Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clinical microbiology reviews. 2019;32(2):e00084-18. https://doi.org/10.1128/CMR.00084-18.
[21] Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. Jama. 2022;327(7):639-51. https://doi.org/10.1001/jama.2022.0470.
International Journal of Scientific Research in Dental and Medical Sciences
Volume 4, Issue 2
June 2022
Pages 57-66

Files

History

  • Receive Date: 17 March 2022
  • Revise Date: 02 May 2022
  • Accept Date: 26 May 2022

Share

How to cite

Statistics